1. Home
  2. NEPH vs BYSI Comparison

NEPH vs BYSI Comparison

Compare NEPH & BYSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$4.26

Market Cap

40.1M

Sector

Health Care

ML Signal

HOLD

Logo BeyondSpring Inc.

BYSI

BeyondSpring Inc.

N/A

Current Price

$0.75

Market Cap

35.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NEPH
BYSI
Founded
1997
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.1M
35.8M
IPO Year
2004
2016

Fundamental Metrics

Financial Performance
Metric
NEPH
BYSI
Price
$4.26
$0.75
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
30.6K
1.9M
Earning Date
05-08-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
1000.00
N/A
EPS
0.12
N/A
Revenue
$18,789,000.00
N/A
Revenue This Year
$11.24
N/A
Revenue Next Year
$11.58
N/A
P/E Ratio
$35.17
N/A
Revenue Growth
32.67
N/A
52 Week Low
$2.66
$0.67
52 Week High
$6.42
$2.44

Technical Indicators

Market Signals
Indicator
NEPH
BYSI
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
NEPH
BYSI

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

About BYSI BeyondSpring Inc.

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It operates in Plinabulin pipeline segment. Its first asset, Plinabulin is a novel brain-penetrant microtubule modulator with dendritic cell maturation and vasculature modulation mechanism, which has the potential to help mitigate acquired resistance from prior immune checkpoint inhibitors (ICI) treatment in cancer patients. It is a Selective Immunomodulating Microtubule-Binding Agent (SIMBA), which may provide multiple therapeutic opportunities.

Share on Social Networks: